| Bioactivity | Naptumomab, a tumor targeting superantigen (TTS), is a fusion protein containing. Naptumomab stimulates the immune system to identify and kill tumour cells. Naptumomab can be used for the research of refractory solid tumors such as renal cell carcinoma[1][2]. |
| Name | Naptumomab |
| CAS | 1412892-09-1 |
| Storage | Please store the product under the recommended conditions in the Certificate of Analysis. |
| Reference | [1]. Matthew K Robinson, et al. Naptumomab estafenatox: a new immunoconjugate. Expert Opin Biol Ther. 2010 Feb;10(2):273-9. [2]. Tim Eisen, et al. Naptumomab estafenatox: targeted immunotherapy with a novel immunotoxin. Curr Oncol Rep. 2014 Feb;16(2):370. |